AbbVie (NYSE:ABBV) Releases Earnings Results, Misses Estimates By $0.82 EPS

AbbVie (NYSE:ABBV) released its quarterly earnings results on Friday. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82), RTT News reports. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. During the same period in the prior year, the business posted $2.79 earnings per share. AbbVie updated its FY 2025 guidance to 12.120-12.320 EPS.

AbbVie Stock Up 5.2 %

NYSE:ABBV traded up $9.19 during mid-day trading on Friday, hitting $184.84. 6,787,204 shares of the company’s stock were exchanged, compared to its average volume of 5,945,484. The company has a market cap of $326.63 billion, a PE ratio of 64.14, a P/E/G ratio of 1.77 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. AbbVie has a one year low of $153.58 and a one year high of $207.32. The business has a fifty day moving average price of $176.43 and a 200 day moving average price of $184.84.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Barclays lifted their price objective on AbbVie from $200.00 to $212.00 and gave the stock an “overweight” rating in a research report on Monday, October 7th. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Morgan Stanley reduced their target price on AbbVie from $231.00 to $224.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Truist Financial reduced their target price on AbbVie from $215.00 to $211.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, UBS Group raised their target price on AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average target price of $205.00.

Insider Buying and Selling at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.